GLP-1

Ozempic Insulin injection pen
#Diabetes #GLP-1 #Neuroscience #Obesity #Society for Neuroscience #Weight loss

News from SfN’s Neuroscience 2024: The brain on GLP-1 agonists

Diabetes and weight loss drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists have widespread effects in the brain, with new research presented at the Society for Neuroscience’s Neuroscience 2024 uncovering potential novel therapeutic benefits and behavioural side effects. About one in eight adults… Read More

#News #Trending News

Weight loss concept
#Diabetes #GLP-1 #Obesity #Weight loss

GLP-1 receptor agonists: Buying into the hype

As further news comes out about the benefits that the diabetes and weight-loss drug Ozempic offers patients, it’s hard not to get caught up in the hype surrounding a therapy many are calling a 'wonder drug'. Of course, it’s not the first time the pharmaceutical industry has produced a therapy… Read More

#Exclusive Content

Dorte Gram
#Fundraising #GLP-1 #Novo Nordisk #Obesity #Pila Pharma #Weight loss

Scientist who discovered Ozempic to study new obesity drug

Dorte Gram, founder of Pila Pharma and a former Novo Nordisk researcher who identified the molecule that became semaglutide, the active ingredient in Ozempic and Wegovy, has raised 10 million SEK ($980,320) for a novel obesity-related study. The money will allow the company to study drug… Read More

#News

Obese man measures his waist
#European Association for the Study of Diabetes #GLP-1 #Obesity #Phase I trial #QL Biopharm

QL Biopharm announces new obesity drug results

QL Biopharm, a clinical stage biopharmaceutical company developing biologic drugs for the treatment of metabolic diseases, has shared Phase Ic clinical data for its lead drug candidate ZT002. The data was presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024, Madrid,… Read More

#News #Trending News

#Clinical trial #Clinical trials #GLP-1 #Phase I trial #Phase II trial

New DDW Highlights podcast: 10 September 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the release of clinical study results that led some media titles to ask… Read More

#News

#Clinical trial #Clinical trials #GLP-1 #Phase I trial #Phase II trial

New DDW Highlights vodcast: 10 September 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   With the release of clinical… Read More

#News

#Clinical trial #Clinical trials #GLP-1 #Phase I trial #Phase II trial

This week in drug discovery (2-6 September) 

News round-up for 2-6 September by DDW Senior Digital Content Editor Diana Spencer. With the release of clinical study results that led some media titles to ask if semaglutide could be a ‘fountain of youth’, this week our news highlights focus on clinical trials at a variety of… Read More

#News

Ozempic (semaglutide)
#Cardiovascular disease #Covid-19 #Diabetes #GLP-1 #Weight loss

Semaglutide reduces risk of all-cause death

Semaglutide has been found to reduce the rates of all-cause death, including as a result of Covid-19, in those who are overweight or have obesity and established cardiovascular disease without diabetes. The findings were published in JACC, the journal of the American College… Read More

#News #Trending News

Cancer research
#Diabetes #GLP-1 #Korea #Obesity #Phase I trial #Small molecules #Yunovia

Small molecule GLP-1 agonist shows superior tolerability

Yunovia (a subsidiary of Ildong Pharmaceutical Group) has received permission from the Ministry of Food and Drug Safety (MFDS) of Korea to begin a Phase I study for its small molecule glucagon-like peptide-1 (GLP-1) agonist for obesity and diabetes. The Phase I Multiple Ascending Dose (MAD) study will be conducted… Read More

#Editor's Choice #News #Regulatory

Monoclonal antibodies
#GLP-1 #Monoclonal antibodies #Obesity #Phase II trial #Skye Bioscience #Weight loss

Monoclonal antibody CB1 inhibitor for obesity enters Phase II trials

Skye Bioscience has started screening patients for a Phase II clinical trial (CBeyond) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody. The study will assess the ability of nimacimab as a next-generation weight loss therapeutic to safely and effectively reduce weight in… Read More

#Editor's Choice #News

Human heart
#Cardiovascular disease #GLP-1 #Heart failure #Obesity #University College London #Weight loss

Semaglutide could also benefit patients with heart failure

A new study indicates that anti-obesity drug semaglutide helps prevent cardiac events among overweight people who have cardiovascular disease, even if they also have heart failure. The results follow a previous finding that weekly injections of semaglutide were linked to a 20% reduction in major adverse cardiac events (MACE) such… Read More

#News #Trending News

Patient injects Ozempic
#Adverse event #Diabetes #GLP-1 #Obesity #Weight loss

Semaglutide found to increase risk of suicidal thoughts

A new study has suggested a link between semaglutide (the active ingredient in Wegovy and Ozempic) and a disproportionately increased reporting of suicidality. Semaglutide has recently been treated as something of a wonder drug, with studies demonstrating it can reduce the risk of cardiovascular disease,… Read More

#News #Trending News

Woman tests blood glucose level
#Diabetes #Eli Lilly #GLP-1 #Obesity #Phase III trial #Weight loss

Weight loss drug reduced type 2 diabetes risk by 94%

Topline results from the SURMOUNT-1 three-year study have shown that tirzepatide (Zepbound and Mounjaro) significantly reduced the risk of progression to type 2 diabetes by 94% among adults with pre-diabetes and obesity or overweight. Additionally, treatment with tirzepatide resulted in sustained weight loss through the treatment… Read More

#News

#Alzheimer's #Cardiovascular disease #GLP-1 #Liver disease #Nicotine addiction #Obesity #Weight loss

New DDW Highlights vodcast: 7 August 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   GLP-1 receptor agonists have dominated… Read More

#News

#Alzheimer's #Cardiovascular disease #GLP-1 #Liver disease #Nicotine addiction #Obesity #Weight loss

New DDW Highlights podcast: 5 August 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. GLP-1 receptor agonists have dominated the headlines this week, with data revealed on… Read More

#News

#Alzheimer's #Cardiovascular disease #GLP-1 #Liver disease #Nicotine addiction #Obesity #Weight loss

This week in drug discovery (29 July – 2 August) 

News round-up for 29 July – 2 August by DDW Senior Digital Content Editor Diana Spencer. GLP-1 receptor agonists have dominated the headlines this week, with data revealed on new potential beneficial effects of treatment with semaglutide and dual receptor agonists like pemvidutide. The top stories:… Read More

#News